289 related articles for article (PubMed ID: 11406915)
1. Risedronate: clinical usage.
Chapurlat RD; Delmas PD
Int J Clin Pract; 2001 May; 55(4):275-8. PubMed ID: 11406915
[TBL] [Abstract][Full Text] [Related]
2. Risedronate: a review of its pharmacological properties and clinical use in resorptive bone disease.
Dunn CJ; Goa KL
Drugs; 2001; 61(5):685-712. PubMed ID: 11368289
[TBL] [Abstract][Full Text] [Related]
3. Risedronate: a new oral bisphosphonate.
Umland EM; Boyce EG
Clin Ther; 2001 Sep; 23(9):1409-21. PubMed ID: 11589256
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis.
Iwamoto J; Takeda T; Sato Y
Curr Med Res Opin; 2006 May; 22(5):919-28. PubMed ID: 16709313
[TBL] [Abstract][Full Text] [Related]
5. Risedronate: a clinical review.
Crandall C
Arch Intern Med; 2001 Feb; 161(3):353-60. PubMed ID: 11176760
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of risedronate in reducing fracture risk in osteoporotic women aged 80 and older: implications for the use of antiresorptive agents in the old and oldest old.
Boonen S; McClung MR; Eastell R; El-Hajj Fuleihan G; Barton IP; Delmas P
J Am Geriatr Soc; 2004 Nov; 52(11):1832-9. PubMed ID: 15507059
[TBL] [Abstract][Full Text] [Related]
7. Risedronate in the treatment of Paget's disease of bone: an open label, multicenter study.
Siris ES; Chines AA; Altman RD; Brown JP; Johnston CC; Lang R; McClung MR; Mallette LE; Miller PD; Ryan WG; Singer FR; Tucci JR; Eusebio RA; Bekker PJ
J Bone Miner Res; 1998 Jun; 13(6):1032-8. PubMed ID: 9626635
[TBL] [Abstract][Full Text] [Related]
8. Risedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosis.
Harrington JT; Ste-Marie LG; Brandi ML; Civitelli R; Fardellone P; Grauer A; Barton I; Boonen S
Calcif Tissue Int; 2004 Feb; 74(2):129-35. PubMed ID: 14648009
[TBL] [Abstract][Full Text] [Related]
9. Risedronate reduces the risk of first vertebral fracture in osteoporotic women.
Heaney RP; Zizic TM; Fogelman I; Olszynski WP; Geusens P; Kasibhatla C; Alsayed N; Isaia G; Davie MW; Chesnut CH
Osteoporos Int; 2002; 13(6):501-5. PubMed ID: 12107665
[TBL] [Abstract][Full Text] [Related]
10. Aging bone and osteoporosis: strategies for preventing fractures in the elderly.
Ettinger MP
Arch Intern Med; 2003 Oct; 163(18):2237-46. PubMed ID: 14557222
[TBL] [Abstract][Full Text] [Related]
11. Risedronate for Paget's disease of bone.
Med Lett Drugs Ther; 1998 Aug; 40(1034):87-8. PubMed ID: 9731243
[No Abstract] [Full Text] [Related]
12. A comparison of the effect of risedronate and etidronate on lumbar bone mineral density in Japanese patients with osteoporosis: a randomized controlled trial.
Fukunaga M; Kushida K; Kishimoto H; Shiraki M; Taketani Y; Minaguchi H; Inoue T; Morita R; Morii H; Yamamoto K; Ohashi Y; Orimo H;
Osteoporos Int; 2002 Dec; 13(12):971-9. PubMed ID: 12459940
[TBL] [Abstract][Full Text] [Related]
13. Pharmacoeconomic analysis of osteoporosis treatment with risedronate.
Brecht JG; Kruse HP; Felsenberg D; Möhrke W; Oestreich A; Huppertz E
Int J Clin Pharmacol Res; 2003; 23(4):93-105. PubMed ID: 15224498
[TBL] [Abstract][Full Text] [Related]
14. [Risedronate, a new diphosphonate in osteoporosis and Paget's disease].
Bannwarth B
Presse Med; 2002 Mar; 31(8):340-2. PubMed ID: 11913075
[No Abstract] [Full Text] [Related]
15. Health-economic comparison of three recommended drugs for the treatment of osteoporosis.
Brecht JG; Kruse HP; Möhrke W; Oestreich A; Huppertz E
Int J Clin Pharmacol Res; 2004; 24(1):1-10. PubMed ID: 15575171
[TBL] [Abstract][Full Text] [Related]
16. The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis.
Brown JP; Kendler DL; McClung MR; Emkey RD; Adachi JD; Bolognese MA; Li Z; Balske A; Lindsay R
Calcif Tissue Int; 2002 Aug; 71(2):103-11. PubMed ID: 12085156
[TBL] [Abstract][Full Text] [Related]
17. A review of Paget's disease of bone with a focus on the efficacy and safety of zoledronic acid 5 mg.
Abelson A
Curr Med Res Opin; 2008 Mar; 24(3):695-705. PubMed ID: 18226324
[TBL] [Abstract][Full Text] [Related]
18. Periodontal assessment of postmenopausal women receiving risedronate.
Palomo L; Bissada NF; Liu J
Menopause; 2005; 12(6):685-90. PubMed ID: 16278611
[TBL] [Abstract][Full Text] [Related]
19. Risedronate prevents bone loss in early postmenopausal women: a prospective randomized, placebo-controlled trial.
Hooper MJ; Ebeling PR; Roberts AP; Graham JJ; Nicholson GC; D'Emden M; Ernst TF; Wenderoth D
Climacteric; 2005 Sep; 8(3):251-62. PubMed ID: 16390757
[TBL] [Abstract][Full Text] [Related]
20. Five years of treatment with risedronate and its effects on bone safety in women with postmenopausal osteoporosis.
Ste-Marie LG; Sod E; Johnson T; Chines A
Calcif Tissue Int; 2004 Dec; 75(6):469-76. PubMed ID: 15478000
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
